Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Transcriptional regulator combination

A pharmaceutical composition, prostate cancer technology, applied in the direction of drug combination, plant raw materials, plant/algae/fungus/moss components, etc., can solve short-term effects and other problems

Inactive Publication Date: 2012-09-12
ACAD SINIC
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, since AR expressed by cancer cells often becomes androgen-independent, ie constitutively active (eg due to mutation), its effects are often short-lived

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transcriptional regulator combination
  • Transcriptional regulator combination
  • Transcriptional regulator combination

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0212] Example 1 Production and Characterization of Prostate Cancer Reporter Cell Line

[0213] 22Rvl cell line was purchased from ATCC. The informant plasmid (p5.7kb-PSA-Luc) was constructed by inserting the 5.7kb PSA promoter into the pGL3 plasmid (Promega). The 22RvPSA36-103 cell line was generated by stably transfecting p5.7kb-PSA-Luc and pGK-puro into 22Rvl cells and selected for purulins as described (Fryer and Archer, 1998).

[0214] For luciferase activity assay, 8 x 10 4 Cells derived from 22Rvl were grown in 48-well multiwell dishes. Cell culture medium was RPMI containing 5% charcoal-coated dextran-adsorbed fetal bovine serum (Hyclone). After the cells had grown in culture for one day, their growth medium was changed to include experimental or control compositions as described below, and cell growth was continued for an additional 20 hours. Cells were lysed by adding passive lysis buffer (Promega), followed by luciferase detection system (Promega) and VICTOR 2 ...

example 2

[0216] Example 2 Androgen induces AR to interact with IKKα

[0217] The inventors investigated whether IKKα or IKKβ could interact with activated AR in 22Rv / PSA36-103 cells after androgen stimulation. Co-immunoprecipitation of AR in complexes with IKKα was detected after exposing cells to 10 nM of 5α dihydrotestosterone for five minutes. AR-associated IKKα levels accumulated and peaked within 10 to 15 minutes, then decreased after 30 minutes, and completely decreased after 60 minutes. In contrast, IKKβ was detected at only very low levels in the AR complex at all time points. AR and IKKα co-localized in the nucleus as determined by indirect immunofluorescent staining using AR and IKKα antibodies. Their colocalization was followed by a time course similar to that determined from co-immunoprecipitation of the proteins.

[0218] The results collectively demonstrate that AR activation induces complex formation between AR and IKKα in the nucleus to activate androgen-responsive t...

example 3

[0219] Example 3 IKKα inhibition reduces androgen response enhancer activity

[0220] Detection of the tested IKK inhibitor 15-deoxy-Δ using luciferase as described above 12,14 - Prostaglandin J 2 , prostaglandin A1 and the ability of leaf-containing wedelolide to inhibit the activity of androgen response enhancers. The compound inhibits 5α-dihydrotestosterone-induced luciferase expression in a dose-dependent manner. In contrast, the IKK-β-specific inhibitor SC-514 had no effect on androgen response enhancer activity at any of the concentrations tested. This result suggests that the AR signal transduction pathway acts specifically through IKKα.

[0221] To confirm this conclusion, the inventors constructed a 22RvPSA36-103 cell line capable of inducing RNAi-knockout of IKKα or IKKβ.

[0222] The small hairpin RNA Ai expression system used by the inventors is a modification of an inducible expression system reported elsewhere (van de Wetering et al., 2003). Use the followin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for treating androgen simulated diseases of a subject through delivering a combination containing an effective dose of I Kappa B kinase subunit alpha active inhibitors to the subject who needs treatment, which can also be used for reducing the risk of prostatic cancer of a subject through delivering the combination to the subject with high risk of prostatic cancer. The invention also relates to a method for recognizing a regulator of I Kappa B kinase subunit alpha regulated transcriptional activity. The invention also relates to a method for determining the I Kappa B kinase subunit alpha regulated transcriptional activity in nonhuman mammal test subjects.

Description

[0001] This application is a divisional application of Chinese patent application 200710109268.9 (invention name: transcription regulator composition) with the filing date of May 30, 2007. technical field [0002] The present invention relates to a transcription regulator composition. Background technique [0003] Androgens are defined as a broad class of steroid hormones that primarily control the development and maintenance of male characteristics. It exerts its physiological effects via the androgen receptor (AR), a member of the superfamily of steroid hormone nuclear receptors. The AR is activated by binding an androgen (eg, testosterone) or a related ligand. Activated AR initiates signal transduction pathways that drive increased transcription of numerous "androgen-responsive" target genes such as prostate-specific antigen (PSA). It should be noted that the signal transduction steps in this pathway have not been fully elucidated. [0004] Activation of the AR by andr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K36/28A61K31/366A61K31/352A61P13/08A61P35/00
Inventor 萧培文
Owner ACAD SINIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com